Pharmacokinetics and Pharmacodynamics Estimation of Eculizumab in a 2-Year-Old Girl With Atypical Hemolytic Uremic Syndrome: A Case Report With 4-Year Follow-Up

• Autors principals: Ken Saida (Autor), Tsuyoshi Fukuda (Autor), Kana Mizuno (Autor), Masao Ogura (Autor), Koichi Kamei (Autor), Shuichi Ito (Autor)
• Format: Llibre
• Publicat: Frontiers Media S.A., 2019-12-01T00:00:00Z.
• Matèries: article
• Accés en línia: Connect to this object online.

Background: Eculizumab has dramatically changed poor outcomes of complement-mediated atypical hemolytic uremic syndrome (aHUS) as first-line treatment. Discontinuation of eculizumab remains challenging, and doctor's visits every 2 weeks for intravenous injection because of standard dosing proto...